recombinant fowlpox-TRICOM

Recombinant fowlpox-TRICOM is a cancer immunotherapy vaccine that uses a genetically engineered, non-replicating fowlpox virus as a vector to deliver three human T-cell co-stimulatory molecule genes—B7.1 (CD80), ICAM-1 (CD54), and LFA-3 (CD58)—collectively known as TRICOM. The purpose of this vaccine is to enhance the immune system’s response against tumor cells by improving antigen presentation and T-cell activation. It has been studied both alone and in combination with other poxvirus-based vaccines encoding tumor antigens such as prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), or mucin 1 (MUC1). Recombinant fowlpox vectors are typically used for booster vaccinations following priming with vaccinia-based vectors in prime/boost regimens, aiming to generate robust anti-tumor immunity while minimizing anti-vector immunity. The approach has been evaluated in multiple phase I and II clinical trials for various cancers, including metastatic prostate cancer, melanoma, bladder cancer, and solid tumors[1][2][3][4][5][6].

Other names

recombinant fowlpox-TRICOM vaccinerF-TRICOM